https://scholars.lib.ntu.edu.tw/handle/123456789/452739
標題: | The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass | 作者: | Chan K.K.L. CHI-AN CHEN Nam J.-H. Ochiai K. Wilailak S. Choon A.-T. Sabaratnam S. Hebbar S. Sickan J. Schodin B.A. Sumpaico W.W. |
公開日期: | 2013 | 卷: | 239 | 期: | 244 | 起(迄)頁: | 239-244 | 來源出版物: | Gynecologic Oncology | 摘要: | Objective: The purpose of this study was to evaluate the performance of human epididymis protein 4 (HE4) and the Risk of Ovarian Malignancy Algorithm (ROMA) for distinguishing between benign and malignant pelvis masses in Asian women. Methods: This was a prospective, multicenter (n = 6) study with patients from six Asian countries. Patients had a pelvic mass on imaging and were scheduled to undergo surgery. Serum CA125 and HE4 were measured on preoperative samples. CA125, HE4, and ROMA were evaluated for sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV). Results: A total of 414 women with an adnexal mass were evaluated, of which 65 had epithelial ovarian (EOC) cancer, 16 had borderline tumors and 11 had other malignant diseases. Compared to CA125, HE4 had lower sensitivity (56.9% vs 90.8%) and NPV (91.8% vs 97.3%), but improved specificity (96.9% vs 67.1%) and PPV (78.7% vs 35.8%) for differentiating between benign pelvic mass and EOC. ROMA had similar sensitivity (89.2% vs 90.8%) and NPV (97.6% vs 97.3%) as CA125, but showed improved specificity (87.3% vs 67.1%) and PPV (58.6% vs 35.8%). ROMA accurately predicted 87.3% of benign cases as low risk, and 82.6% of stage I/II EOC and 89.2% of all EOC as high risk. Conclusion: ROMA showed similar sensitivity as CA125 but improved specificity and PPV, especially in premenopausal women. Using ROMA may help predict if a pelvic mass is benign or malignant and facilitate subsequent management planning. ? 2012 Elsevier Inc. All rights reserved. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/452739 | DOI: | 10.1016/j.ygyno.2012.09.034 | SDG/關鍵字: | CA 125 antigen; human epididymis protein 4; adenofibroma; adult; aged; article; Asian; cancer diagnosis; cancer risk; cancer staging; clinical assessment tool; cyst; cystadenoma; diagnostic accuracy; diagnostic test accuracy study; differential diagnosis; endometriosis; female; fibroma; high risk patient; Hong Kong; human; hydrosalpinx; Japan; Korea; leiomyoma; major clinical study; ovary cancer; ovary carcinoma; ovary tumor; pelvis tumor; Philippines; predictive value; premenopause; priority journal; prospective study; protein blood level; risk assessment; risk of ovarian malignancy algorithm; sensitivity and specificity; Taiwan; teratoma; Thailand; tuboovarian abscess; Algorithms; CA-125 Antigen; Female; Humans; Membrane Proteins; Neoplasms, Glandular and Epithelial; Ovarian Diseases; Ovarian Neoplasms; Predictive Value of Tests; Prospective Studies; Proteins; ROC Curve; Tumor Markers, Biological |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。